For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo Launches Memary(R) 5mg, 10mg and 20mg Tablets for the Treatment of Alzheimer’s Disease in Japan

TOKYO, Japan (June 8, 2011) － Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), today announced that it has launched Memary^® 5mg, 10mg and 20mg Tablets (generic name: Memantine Hydrochloride, Approval to Manufacture and Market: January 21, 2011, Drug Price Listing: March 11, 2011) given once daily for the treatment of moderate to severe Alzheimer's Disease (AD) in Japan on Wednesday, June 8.

 

Memary was discovered by Merz Pharmaceuticals GmbH (head office, Germany) and is the only N-methyl-D-aspartate (NMDA) receptor antagonist in the world used for the treatment of moderate to severe AD. This drug was approved for use in the treatment of patients with AD by the European EMA in 2002 and by the U.S. FDA in 2003. It is marketed in 70 countries around the world and is positioned as a standard care pharmaceutical for moderate to severe AD.

 

By offering a new treatment option with a distinct mechanism for the treatment of AD in Japan, Daiichi Sankyo is confident that it can reduce unmet needs and contribute to improving quality of life for patients and their families.

 

Memary® Overview

Product Name	MEMARY® TABLETS 5 mg, 10 mg, 20 mg
Generic Name	Memantine Hydrochloride
Price Listing	Memary® 5mg: ￥133.9 per tablet  Memary® 10mg: ￥239.2 per tablet  Memary® 20mg: ￥427.5 per tablet
Indication	Treatment of moderate to severe Alzheimer's Disease
Dosage and  Administration	Generally, the starting dose of 5 mg is administrated orally once a day. The maintenance dose of 20 mg is achieved by upward titration of 5 mg per week.
Approval Date	January 21, 2011
Remarks	Memantine is licensed from Merz Pharmaceuticals GmbH